Generic placeholder image

Current Topics in Medicinal Chemistry

Author(s): Bingbing Li, Deqin Rong and Yuanxiang Wang*

DOI: 10.2174/1568026619666191011163410

DownloadDownload PDF Flyer Cite As
Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors

Page: [1872 - 1876] Pages: 5

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

PPIs are involved in diverse biochemical events and perform their functions through the formation of protein-protein complexes or PPI networks. The large and flat interacting surfaces of PPIs make discovery of small-molecule modulators a challenging task. New strategies and more effective chemical technologies are needed to facilitate the development of PPIs small-molecule inhibitors. Covalent modification of a nucleophilic residue located proximally to the immediate vicinity of PPIs can overcome the disadvantages of large interacting surfaces and provides high-affinity inhibitors with increased duration of action and prolonged target modulation. On the other hand, covalent inhibitors that target non-conserved protein residues demonstrate improved selectivity over related protein family members. Herein, we highlight the latest progress of small-molecule covalent PPIs inhibitors and hope to shed light on future PPIs inhibitor design and development. The relevant challenges and opportunities are also discussed.

Keywords: Protein-protein interaction, covalent inhibitor, cysteine, lysine, methionine, GPCR.

[1]
Arkin, M.R.; Tang, Y.; Wells, J.A. Small-molecule inhibitors of protein-protein interactions: Progressing toward the reality. Chem. Biol., 2014, 21(9), 1102-1114.
[http://dx.doi.org/10.1016/j.chembiol.2014.09.001] [PMID: 25237857]
[2]
Lonsdale, R.; Ward, R.A. Structure-based design of targeted covalent inhibitors. Chem. Soc. Rev., 2018, 47(11), 3816-3830.
[http://dx.doi.org/10.1039/C7CS00220C] [PMID: 29620097]
[3]
Wang, Y.; Kaiser, C.E.; Frett, B.; Li, H.Y. Targeting mutant KRAS for anticancer therapeutics: A review of novel small molecule modulators. J. Med. Chem., 2013, 56(13), 5219-5230.
[http://dx.doi.org/10.1021/jm3017706] [PMID: 23566315]
[4]
Ye, N.; Zhou, J. KRAS - an evolving cancer target. Austin J. Cancer Clin. Res., 2014, 1(1), 1004.
[PMID: 27642639]
[5]
Ni, D.; Li, X.; He, X.; Zhang, H.; Zhang, J.; Lu, S. Drugging K-RasG12C through covalent inhibitors: Mission possible? Pharmacol. Ther., 2019, 202, 1-17.
[http://dx.doi.org/10.1016/j.pharmthera.2019.06.007] [PMID: 31233765]
[6]
Patricelli, M.P.; Janes, M.R.; Li, L.S.; Hansen, R.; Peters, U.; Kessler, L.V.; Chen, Y.; Kucharski, J.M.; Feng, J.; Ely, T.; Chen, J.H.; Firdaus, S.J.; Babbar, A.; Ren, P.; Liu, Y. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov., 2016, 6(3), 316-329.
[http://dx.doi.org/10.1158/2159-8290.CD-15-1105] [PMID: 26739882]
[7]
Janes, M.R.; Zhang, J.; Li, L.S.; Hansen, R.; Peters, U.; Guo, X.; Chen, Y.; Babbar, A.; Firdaus, S.J.; Darjania, L.; Feng, J.; Chen, J.H.; Li, S.; Li, S.; Long, Y.O.; Thach, C.; Liu, Y.; Zarieh, A.; Ely, T.; Kucharski, J.M.; Kessler, L.V.; Wu, T.; Yu, K.; Wang, Y.; Yao, Y.; Deng, X.; Zarrinkar, P.P.; Brehmer, D.; Dhanak, D.; Lorenzi, M.V.; Hu-Lowe, D.; Patricelli, M.P.; Ren, P.; Liu, Y. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell, 2018, 172(3), 578-589.e17.
[http://dx.doi.org/10.1016/j.cell.2018.01.006] [PMID: 29373830]
[8]
Fakih, M.; O’Neil, B.; Price, T.J.; Falchook, G.S.; Desai, J.; Kuo, J.; Govindan, R.; Rasmussen, E.; Morrow, P.K.H.; Ngang, J.; Henary, H.A.; Hong, D.S. Phase 1 study evaluating the safety, tolerability, pharmacokinetics and efficacy of AMG 510, a novel small molecule KRAS G12C inhibitor, in advanced solid tumors. J. Clin. Oncol., 2019, 37(Suppl. 15), 3003-3003.
[http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.3003]
[9]
Mirati Therapeutic, Inc. Structure-Based Drug Discovery of MRTX1257, a Selective, Covalent KRAS G12C Inhibitor with Oral Activity in Animal Models of Cancer. https://www. mirati.com/wp-content/uploads/2018/12/KRAS-Poster-AACR-RAS.pdf
[10]
Cory, S.; Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2002, 2(9), 647-656.
[http://dx.doi.org/10.1038/nrc883] [PMID: 12209154]
[11]
Wan, Y.; Dai, N.; Tang, Z.; Fang, H. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents. Eur. J. Med. Chem., 2018, 146, 471-482.
[http://dx.doi.org/10.1016/j.ejmech.2018.01.076] [PMID: 29407973]
[12]
Hird, A.W.; Tron, A.E. Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacol. Ther., 2019, 198, 59-67.
[http://dx.doi.org/10.1016/j.pharmthera.2019.02.007] [PMID: 30790641]
[13]
Friberg, A.; Vigil, D.; Zhao, B.; Daniels, R.N.; Burke, J.P.; Garcia-Barrantes, P.M.; Camper, D.; Chauder, B.A.; Lee, T.; Olejniczak, E.T.; Fesik, S.W. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J. Med. Chem., 2013, 56(1), 15-30.
[http://dx.doi.org/10.1021/jm301448p] [PMID: 23244564]
[14]
G.; Belmonte, M. A.; Aquila, B.; Chuaqui, C.; Hird, A. W.; Lamb, M. L.; Rawlins P. B.; Su, N.; Tentarelli, S.; Grimster, N. P.; Su, Q. Inhibition of MCL-1 through covalent modification of a noncatalytic lysine side chain. Nat. Chem. Biol., 2016, 12, 931-936.
[http://dx.doi.org/10.1038/nchembio.2174]
[15]
Doroshow, D.B.; Eder, J.P.; LoRusso, P.M. BET inhibitors: a novel epigenetic approach. Ann. Oncol., 2017, 28(8), 1776-1787.
[http://dx.doi.org/10.1093/annonc/mdx157] [PMID: 28838216]
[16]
Liu, Z.; Wang, P.; Chen, H.; Wold, E.A.; Tian, B.; Brasier, A.R.; Zhou, J. Drug discovery targeting bromodomain-containing protein 4. J. Med. Chem., 2017, 60(11), 4533-4558.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01761] [PMID: 28195723]
[17]
Wang, P.; Zhou, J. Proteolysis Targeting chimera (PROTAC): A paradigm-shifting approach in small molecule drug discovery. Curr. Top. Med. Chem., 2018, 18(16), 1354-1356.
[http://dx.doi.org/10.2174/1568026618666181010101922] [PMID: 30306871]
[18]
Alferiev, I.S.; Hinson, J.T.; Ogle, M.; Breuer, E.; Levy, R.J. High reactivity of alkyl sulfides towards epoxides under conditions of collagen fixation--a convenient approach to 2-amino-4-butyrolactones. Biomaterials, 2001, 22(18), 2501-2506.
[http://dx.doi.org/10.1016/S0142-9612(00)00440-3] [PMID: 11516082]
[19]
Liu, S. Preparation of heterocyclic compounds as bromodomain inhibitors. Resverlogix Corp, WO, 2014, 2014096965, A2.
[20]
Kharenko, O.A.; Patel, R.G.; Brown, S.D.; Calosing, C.; White, A.; Lakshminarasimhan, D.; Suto, R.K.; Duffy, B.C.; Kitchen, D.B.; McLure, K.G.; Hansen, H.C.; van der Horst, E.H.; Young, P.R. Patel, R. G.; David Brown, S.; Calosing, C.; White, A.; Lakshminarasimhan, D.; Suto, R. K.; Duffy, B. C.;Kitchen, D.B.; McLure, K. G.; Hansen, H.C.; van der Horst, E. H.; Young,P. R. Design and characterization of novel covalent bromodomain and extra-terminal domain (BET) inhibitors targeting a methionine. J. Med. Chem., 2018, 61(18), 8202-8211.
[http://dx.doi.org/10.1021/acs.jmedchem.8b00666] [PMID: 30165024]